Autoimmune Diseases are a group of diseases caused by the immune system mistakenly attacking its tissues, including Rheumatoid Arthritis, Systemic Lupus Erythematosus, Multiple Sclerosis, and Inflammatory Bowel Disease. These diseases not only seriously affect the quality of life of patients, but also impose a huge burden on the social healthcare system. In recent years, with the rapid development of Immunology, Molecular Biology and Biotechnology, scientists have gained a deeper understanding of the pathogenesis of Autoimmune Diseases, and have also developed many novel therapeutic tools.

Research on biomarkers and antibody drug targets for Autoimmune Diseases will continue to intensify. This article will explore the latest advances in these areas and consider future directions.

I. Biomarkers of Autoimmune Diseases

Biomarker is an indicator that objectively measures and evaluates a normal biological process, a pathological process, or a response to a therapeutic intervention. In Autoimmune Diseases, biomarkers are used not only for the diagnosis of the disease, but also for assessing disease activity, predicting prognosis and guiding therapy.
 

Cytokines and Chemokines are key signalling molecules in the immune system that play an important role in inflammation and immune response. Here are some of the cytokines that are closely associated with Autoimmune Diseases:
IL-6: IL-6 is highly expressed in diseases such as Rheumatoid Arthritis and Systemic Lupus Erythematosus and promotes inflammatory responses. Anti-IL-6 receptor antibodies (e.g., Tocilizumab) have been used to treat Rheumatoid Arthritis.
IL-17: IL-17 plays a key role in diseases such as psoriasis and ankylosing spondylitis. Anti-IL-17 antibodies (e.g., Secukinumab) have become first-line therapeutic drugs for psoriasis.
TNF-α: TNF-α is a core inflammatory mediator in diseases such as rheumatoid arthritis and inflammatory bowel disease. Anti-TNF-α antibodies (e.g., Infliximab) have been widely used in the clinic.
 

 
 

Autoantibodies are antibodies produced by the immune system when it mistakenly attacks its tissues, and they are diagnostic biomarkers for many autoimmune diseases. Example:
Anti-nuclear antibodies (ANA): used to diagnose Systemic Lupus Erythematosus (SLE).
Anti-double-stranded DNA antibodies (dsDNA): correlate with the activity of SLE.
Anti-neutrophil cytoplasmic antibodies (ANCA): used to diagnose vasculitis.
 

 
 

miRNAs are a class of small molecule RNAs that can regulate gene expression. In recent years, it has been found that miRNAs play an important role in Autoimmune Diseases. For example:
miR-155: highly expressed in Rheumatoid Arthritis and Multiple Sclerosis, promoting inflammatory response.
miR-146a: abnormally expressed in Systemic Lupus Erythematosus, involved in immune regulation.
 

Imbalances in immune cell subpopulations are an important feature of Autoimmune Diseases. Example:
Regulatory T cells (Treg): defective function of Treg cells is associated with a variety of Autoimmune Diseases.
Follicular helper T cells (Tfh): overactivation of Tfh cells leads to high levels of autoantibody production by B cells.
 

In recent years, the relationship between Gut Microbiota and Autoimmune Diseases has attracted much attention. It has been found that dysbiosis of the gut flora is closely related to diseases such as Rheumatoid Arthritis and Inflammatory Bowel Disease. Example:
Prevotella: significantly increased in patients with Rheumatoid Arthritis.
Bacteroides: associated with the development of Inflammatory Bowel Disease.

 

 
 

II. Antibody Drug Targets
Antibody drugs are an important tool in the treatment of autoimmune diseases. They inhibit inflammatory responses and immune damage by specifically targeting key molecules in the immune system. Here are some of the most promising antibody drug targets for the next decade.
 

IL-17 and IL-23 are key cytokines in the Th17 cell pathway, and they play an important role in diseases such as Psoriasis and Ankylosing Spondylitis. Currently, several anti-IL-17 and anti-IL-23 antibodies have been approved and marketed:
Secukinumab: an anti-IL-17A antibody used to treat Psoriasis and Ankylosing Spondylitis.
Guselkumab: anti-IL-23 antibody for the treatment of moderate to severe Psoriasis.

The JAK-STAT pathway is a key pathway for cytokine signalling and is involved in a variety of immune responses.JAK inhibitors suppress inflammatory responses by blocking this pathway. Example:
Tofacitinib: JAK inhibitor used to treat Rheumatoid Arthritis and Ulcerative Colitis.

 

 

CD20 is a signature molecule on the surface of B cells, and anti-CD20 antibodies inhibit autoantibody production by removing B cells. Example:
Rituximab: anti-CD20 antibody used to treat Multiple Sclerosis and Rheumatoid Arthritis.

BAFF is a key factor in B cell survival and differentiation. Anti-BAFF antibodies treat B cell-mediated autoimmune diseases by inhibiting B cell activity. Example:
Belimumab: anti-BAFF antibody used to treat Systemic Lupus Erythematosus.

CTLA-4 and PD-1 are immune checkpoint molecules that play an important role in regulating T cell activity. Example:
Abatacept: a CTLA-4 fusion protein used in the treatment of Rheumatoid Arthritis.

TNF-α is a central inflammatory mediator in autoimmune diseases, and anti-TNF-α antibodies have become first-line therapeutic agents for a variety of diseases. Example:
Infliximab: anti-TNF-α antibody used to treat rheumatoid arthritis and inflammatory bowel disease.

III. Emerging technologies: driving the future of Autoimmune Disease Research

Single-cell sequencing technology can resolve the gene expression profiles of individual cells, helping scientists to identify new subpopulations and markers of immune cells. For example, through single-cell sequencing, researchers have identified new subpopulations of T cells in Rheumatoid Arthritis.

CRISPR/Cas9 technology enables the precise editing of genes for the study of the role of genes in Autoimmune Diseases. For example, by knocking out specific genes, researchers can verify whether they are associated with a disease.

Artificial intelligence and big data analytics can accelerate the discovery and validation of markers and targets. For example, by analyzing large-scale clinical data, AI can predict new therapeutic targets.
 

With the continuous progress and development of scientific research, the research on biomarkers and antibody drug targets of Autoimmune Diseases will continue to be deepened. Biomarkers such as cytokines, autoantibodies and miRNAs, as well as targets such as IL-17, JAK-STAT and CD20 will become the focus of research. Based on the above analysis, we recommend the following biomarker products to help you in your scientific exploration.
 

 

 
Reference：
[1] Qiu Y, Su M, Liu L, et al.Clinical Application of Cytokines in Cancer Immunotherapy.[J].Drug Design, Development and Therapy, 2021.DOI:10.2147/DDDT.S308578.
[2] Forbes J D, Gary V D, Bernstein C N. The Gut Microbiota in Immune-Mediated Inflammatory Diseases[J].Frontiers in Microbiology, 2016, 7(19032).DOI:10.3389/fmicb.2016.01081.
[3] Zoltán Szekanecz, Mcinnes I B, Schett G , et al.Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases [J].Nature Reviews Rheumatology [2025-02-28]. DOI:10.1038/s41584-021-00652-9.
[4] Xiao Z X, Miller J S, Zheng S G. An updated advance of autoantibodies in autoimmune diseases[J].Autoimmunity reviews, 2021, 20(2):102743.DOI:10.1016/j.autrev.2020.102743.
[5] Pauley K M, Cha S, Chan E K L.MicroRNA in autoimmunity and autoimmune diseases[J].Journal of Autoimmunity, 2009, 32(3-4):189-194.DOI:10.1016/j.jaut.2009.02.012.
[6] Zhang X, Chen B D, Zhao L D,et al.The Gut Microbiota: Emerging Evidence in Autoimmune Diseases[J].Trends in Molecular Medicine, 2020, 26(9).DOI:10.1016/j.molmed.2020.04.001.